Biespecifics Talks

1x06: Bispecific Antibodies – Overview of Safety Profile – Infections

Thu, 09 Apr 2026 09:28:11 +0000

This chapter focuses on infections, one of the most important safety considerations in patients receiving bispecific antibody therapy for relapsed and refractory multiple myeloma. It explores why these infections occur, how their incidence and severity may differ across therapies, and which strategies are recommended to assess risk, prevent complications, monitor patients during treatment, and manage infections effectively in clinical practice.

This podcast is an initiative funded by Pfizer as part of its independent research and continuing education grant program. This grant program seeks the complete independence of the initiative, its content, or related actions.

1x05: Bispecific Antibodies – : Overview of Safety Profile – On-Target Off-Tumor Toxicities

Thu, 09 Apr 2026 09:27:59 +0000

This chapter focuses on on-target off-tumor toxicities associated with bispecific antibody therapy in relapsed and refractory multiple myeloma. It explores why these side effects occur, how they vary across different therapeutic targets, and what their clinical impact can be, including cytopenias, hypogammaglobulinemia, and GPRC5D-related toxicities. It also reviews the strategies used to prevent, monitor, and manage these adverse events in clinical practice.

1x04 Bispecific Antibodies – Overview of Safety Profile – Neurological Complications

Thu, 09 Apr 2026 09:27:46 +0000

This chapter focuses on the neurological complications associated with bispecific antibody therapy in relapsed and refractory multiple myeloma, with particular attention to ICANS. It explains why this toxicity occurs, how frequently and severely it may appear, which measures can help reduce its risk, and how clinicians grade and manage it to improve patient safety during treatment.

1x03 Biespecifics talks: Overview of Safety Profile – Cytokine Release Syndrome

Thu, 09 Apr 2026 09:27:28 +0000

This chapter focuses on cytokine release syndrome, one of the best-known side effects of bispecific antibody therapy in relapsed and refractory multiple myeloma. It explains why CRS occurs, how often and how severely it appears across different therapies, which strategies can reduce its risk, and how clinicians assess and manage it to keep treatment as safe as possible.

1x02 Biespecifics talks: Overview of Treatment Efficacy of Different Constructs

Thu, 09 Apr 2026 09:27:18 +0000

This chapter focuses on the efficacy of bispecific antibodies in relapsed and refractory multiple myeloma, examining how the currently approved therapies perform across different patient groups and treatment settings. It explores when these agents may be most useful, what factors influence response and durability, how they might be sequenced with other T-cell–redirecting therapies, and which strategies could help overcome resistance in the future.

1x01: Bispecific Antibodies – A New Treatment Modality for the management of RRMM

Thu, 09 Apr 2026 09:27:03 +0000

This first chapter introduces bispecific antibodies as a new treatment approach for relapsed and refractory multiple myeloma. It explains how these therapies work, why targets such as BCMA and GPRC5D are important, how the currently approved bispecific antibodies differ in their design, and which emerging agents could shape the next generation of treatment.